Skip to content

ALZAMEND NEURO, INC.

ALZN

CIK 0001677077

← back to feed
Revenue (TTM)
—
Q3 Mar 2026
Net Income (TTM)
−$6.94M
+54.6% YoY Q3 Mar 2026
EPS Diluted (TTM)
−$3.91
+91.4% YoY Q3 Mar 2026
Gross Margin
—
Q3 Mar 2026
Operating Margin
—
Q3 Mar 2026
Net Margin
—
Q3 Mar 2026
Free Cash Flow (TTM)
—
Q3 Mar 2026
Cash
$2.71M
Q3 Mar 2026
Total Debt
—
Q3 Mar 2026
Shares Outstanding
3.8M sh
Q3 Mar 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings